Experimental and Developmental Therapeutics
The Experimental and Developmental Therapeutics Program is focused on improving the treatments for cancer. The program includes investigators with expertise ranging from initial target discovery and identification to regulatory approval for new treatments.
The scientific goals of the Experimental and Developmental (EDT) Program are to:
- Discover and validate novel therapeutic targets
- Identify new therapeutic agents and approaches
- Conduct early phase translational clinical trials of novel therapies
The EDT program members have a wide range of expertise, from synthetic organic chemistry and structural biology, through lead identification and IND-enabling studies, obtaining an IND, to conducting clinical trials. These complementary areas of expertise provide the opportunities for cutting-edge translational research.
Tyler Curiel, M.D., M.P.H.
Andrew Brenner, M.D., Ph.D.
Robert Svatek, M.D.